KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biomarin Pharmaceutical (BMRN) Receivables - Net (2016 - 2025)

Biomarin Pharmaceutical's Receivables - Net history spans 17 years, with the latest figure at $908.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 37.5% year-over-year to $908.2 million, compared with a TTM value of $908.2 million through Dec 2025, up 37.5%, and an annual FY2025 reading of $908.2 million, up 37.5% over the prior year.
  • Receivables - Net for Q4 2025 was $908.2 million at Biomarin Pharmaceutical, up from $790.3 million in the prior quarter.
  • The five-year high for Receivables - Net was $908.2 million in Q4 2025, with the low at $373.4 million in Q4 2021.
  • Average Receivables - Net over 5 years is $591.0 million, with a median of $604.1 million recorded in 2023.
  • Year-over-year, Receivables - Net fell 16.72% in 2021 and then soared 39.0% in 2023.
  • Tracing BMRN's Receivables - Net over 5 years: stood at $373.4 million in 2021, then rose by 23.55% to $461.3 million in 2022, then soared by 37.37% to $633.7 million in 2023, then grew by 4.23% to $660.5 million in 2024, then skyrocketed by 37.5% to $908.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Receivables - Net are $908.2 million (Q4 2025), $790.3 million (Q3 2025), and $855.9 million (Q2 2025).